Lung Cancer
Conference Coverage
VIDEO: Alectinib doubles PFS and then some over crizotinib in ALK+ NSCLC
CHICAGO – The standard of care for patients with non–small cell lung cancer positive for the anaplastic lymphoma kinase (ALK) is the ALK inhibitor...
Conference Coverage
Gefitinib bests chemo as adjuvant therapy for early EGFR-mutant NSCLC
Gefitinib is superior to the standard of care chemotherapy for treatment of resected early non–small cell lung cancer harboring an EGFR activating...
Conference Coverage
More early-stage cancer diagnosis since ACA implementation
Though the increase is small, cancer has been detected earlier and more often, indicating future improvements in care.
From the Journals
Consider invasive mediastinal staging in higher risk NSCLC patients, despite guidelines
Mediastinoscopy staging for NSCLC may be cost effective for more patients than guidelines suggest.
Conference Coverage
Salvage chemo for NSCLC more effective after PD-1/PD-L1 inhibitors
GENEVA – Salvage chemotherapy was more effective among patients who had disease progression following immunotherapy in the second line than among...
Conference Coverage
Atezolizumab improves OS in NSCLC with brain metastases
GENEVA – Immune checkpoint inhibitors may improve survival in patients with non–small cell lung cancer (NSCLC) and brain metastases compared with...
News
FDA approves pembrolizumab for first-line advanced NSCLC
The approval was based on an improved overall response rate and progression-free survival in a cohort of 123 patients.
Conference Coverage
Second generation ALK inhibitors show good response in second-line NSCLC
GENEVA – Investigators presented results from a retrospective review of outcomes in patients with ALK-positive NSCLC treated at one of four Swiss...
Conference Coverage
Lung cancer metastatic sites differ by histology, tumor factors
GENEVA – Distinct metastasis patterns emerge in patients with lung cancer, though the study was limited to patients who already has metastasis.
Conference Coverage
G-CSF safe, but antibiotics are more concerning in SCLC
GENEVA – Despite some negative outcomes with G-CSF, it seems to be the preferred treatment over antibiotics.